详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)

137| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：梯队期刊

作者：

机构： [1]Center for Evidence‑Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. [2]Department of Urology, Institute of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. [3]Department of Urology, Haikou People’s Hospital, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570208, China. [4]Department of Urology, the First Affiliated Hospital and College of Clinical Medicine, Henan University of Science and Technology, Luoyang 450052, Henan, China. [5]Department of Urology, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou 450003, China. [6]Department of Urology, the Second Hospital of Dalian Medical University, Dalian 116023, Liaoning, China. [7]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China. [8]Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200120, China. [9]Department of Urology, the People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830002, China. [10]Department of Urology, Huaihe Hospital of Henan University, Kaifeng 475000, Henan, China. [11]Institutes of Evidence‑Based Medicine and Knowledge Translation, Henan University, Kaifeng 475000, Henan, China. [12]Department of Urology, the Second Affiliated Hospital and Second Clinical Medical College of Fujian Medical University, Quanzhou 362000, Fujian, China. [13]Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. [14]Department of Urology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China. [15]Department of Urology, Tianjin First Central Hospital, Tianjin 300190, China. [16]Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China. [17]Department of Urology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004,China. [18]Department of Urology, Qinghai University Affiliated Hospital, Xining 810012, China. [19]Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, China. [20]Department of Urology, Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Urological Diseases in Gansu Province, Lanzhou 730030, China. [21]Department of Urology, Chifeng Cancer Hospital, the Second Affiliated Hospital of Chifeng University, Chifeng 024000, Inner Mongolia Autonomous Region, China. [22]Key Laboratory of Urinary Tract Tumors and Calculi, Department of Urology, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China. [23]Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. [24]Department of Urology, the Second Division of the First Hospital of Jilin University, Changchun 130061, China. [25]Department of Urology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. [26]Department of Urology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China.

出处：

DOI：

ISSN：

关键词： Non-muscle invasive bladder cancer Bladder cancer Transurethral resection of bladder tumor Treatment Surveillance Guideline

摘要：

Non-muscle invasive bladder cancer (NMIBC) is a major type of bladder cancer with a high incidence worldwide, resulting in a great disease burden. Treatment and surveillance are the most important part of NIMBC management. In 2018, we issued "Treatment and surveillance for non-muscle-invasive bladder cancer in China: an evidence-based clinical practice guideline". Since then, various studies on the treatment and surveillance of NMIBC have been published. There is a need to incorporate these materials and also to take into account the relatively limited medical resources in primary medical institutions in China. Developing a version of guideline which takes these two issues into account to promote the management of NMIBC is therefore indicated. We formed a working group of clinical experts and methodologists. Through questionnaire investigation of clinicians including primary medical institutions, 24 clinically concerned issues, involving transurethral resection of bladder tumor (TURBT), intravesical chemotherapy and intravesical immunotherapy of NMIBC, and follow-up and surveillance of the NMIBC patients, were determined for this guideline. Researches and recommendations on the management of NMIBC in databases, guideline development professional societies and monographs were referred to, and the European Association of Urology was used to assess the certainty of generated recommendations. Finally, we issued 29 statements, among which 22 were strong recommendations, and 7 were weak recommendations. These recommendations cover the topics of TURBT, postoperative chemotherapy after TURBT, Bacillus Calmette-Guérin (BCG) immunotherapy after TURBT, combination treatment of BCG and chemotherapy after TURBT, treatment of carcinoma in situ, radical cystectomy, treatment of NMIBC recurrence, and follow-up and surveillance. We hope these recommendations can help promote the treatment and surveillance of NMIBC in China, especially for the primary medical institutions.© 2022. The Author(s).

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 1 区

医学

小类 | 1 区医学：内科

最新[2023]版：

大类 | 2 区医学

小类 | 2 区医学：内科

JCR分区：

出版当年[2022]版：

Q1 MEDICINE, GENERAL & INTERNAL

最新[2023]版：

Q1 MEDICINE, GENERAL & INTERNAL

影响因子： 16.7 最新[2023版] 14.8 最新五年平均 21.1 出版当年[2022版] 12.7 出版当年五年平均 34.915 出版前一年[2021版] 16.7 出版后一年[2023版]

第一作者：

第一作者机构： [1]Center for Evidence‑Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

共同第一作者：

通讯作者：

通讯机构： [1]Center for Evidence‑Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. [2]Department of Urology, Institute of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)

文献详情

相关文献